Boston Scientific BSX Draws Bullish Targets Despite Lawsuit Hit

Boston Scientific Corporation stocks have been trading up by 8.74 percent after strong clinical trial results boosted investor optimism.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading BSX

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways For BSX Traders

Wall Street firms have trimmed Boston Scientific targets into roughly the $85–$105 band but largely kept BSX at Buy, Outperform, or Overweight.
Consensus targets near $97–$99 versus BSX around the low $60s suggest sizable upside if the company executes on its MedTech growth plan.
Pre‑earnings notes flag that core MedTech and U.S. electrophysiology revenue should meet or slightly beat expectations, even as 2026 guidance likely comes down.
A securities class action now hangs over BSX after a 17–18% plunge on 2026/02/04 tied to weak U.S. EP sales and soft 2026 outlook.
Traders who bought BSX between 2025/07/23 and 2026/02/03 are being urged by law firms to consider lead‑plaintiff roles by early May 2026.

Live Update At 14:02:33 EDT: On Wednesday, April 22, 2026 Boston Scientific Corporation stock [NYSE: BSX] is trending up by 8.74%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

BSX has been grinding higher after a nasty reset. Over the past few weeks, Boston Scientific stock has bounced from the low $60s to roughly $64–$65, with recent closes showing a steady uptrend from the 2026/04/21 low at $59.52. That four‑point rebound is meaningful for short‑term trading sentiment.

Intraday, BSX has traded in a tight band around $64.50–$65.00, with repeated rejections just above $65 on the 5‑minute chart. For day traders, that $65 area is the obvious near‑term wall. Every push into that zone has drawn sellers, but importantly, dips toward $64 have been getting bought.

Under the hood, Boston Scientific throws off solid numbers. Revenue is about $20.07B a year with a gross margin near 69%, which is strong for MedTech. EBIT margin of 18.6% and profit margins around 14% say this is a real cash‑machine, not a story stock. BSX generated about $1.36B in quarterly operating cash flow and roughly $1.01B in free cash flow, while keeping leverage moderate with total debt‑to‑equity around 0.47 and interest coverage near 14.9x.

More Breaking News

The trade‑off is valuation. BSX changes hands at a price‑to‑earnings ratio around 31. That’s not cheap, but traders pay up for consistent double‑digit revenue growth of roughly 15–17% over three and five years. For active traders, this sets the stage: a quality earnings engine, a stretched but normal MedTech multiple, and a chart trying to repair damage ahead of the next catalyst.

Why Traders Are Watching BSX Right Now

Boston Scientific is in that classic “high‑quality name with bruised expectations” phase. The core BSX bull case hasn’t vanished. RBC Capital cut its target from $115 to $105, but it kept an Outperform rating and called out strong fundamentals, stable MedTech demand, and confidence in multi‑year double‑digit growth. That’s not a downgrade of the business. It’s a valuation reset.

Other big shops lined up in the same pattern. Truist took its BSX target down slightly to $90 from $92 and still expects Q1 MedTech results to be in line or better than what it called “anxious” expectations. BTIG trimmed to $90 from $110 and stayed at Buy. Mizuho slashed its target to $90 from $115 but remained Outperform on Boston Scientific, framing the move as part of a broad sector clean‑up, not a BSX‑only problem.

Then look at the spread versus where BSX actually trades. Barclays now sits at $100 with an Overweight rating while Boston Scientific changes hands around $61–$65. Across the Street, average targets cluster near $97–$99. That implies a big gap between current price and what analysts think BSX is worth if management can deliver.

But there’s a catch, and this is where short‑term trading gets interesting. Stifel, still at Buy with an $85 target, says near‑term U.S. electrophysiology revenue looks fine, yet 2026 guidance probably needs to come down. At the same time, Boston Scientific now faces a securities class action claiming it overstated the sustainability of U.S. EP growth and downplayed competition. That lawsuit follows a brutal 17.6% single‑day dive on 2026/02/04 after weak EP sales and soft 2026 guidance.

Put together, BSX has turned into a “show‑me” stock. Earnings before the upcoming market open are the next big test. A clean print with stable guidance could spark a relief move toward those trimmed targets. A wobble in EP or another guidance reset, and traders will not hesitate to hit the sell button again.

Conclusion

For active traders, BSX is exactly the kind of mixed story that creates opportunity. On one side, Boston Scientific throws off strong cash, runs fat margins, and grows revenue at a double‑digit clip. Wall Street still largely says Buy, with Boston Scientific targets stacked in the $85–$105 range and consensus close to $97–$99, well above a stock price in the low to mid‑$60s.

On the other side, the U.S. electrophysiology business — once a key growth engine for BSX — is under a cloud. The February 2026 sell‑off, the weaker 2026 guidance, and now multiple securities class actions add legal and headline risk that momentum traders cannot ignore. Every guidance comment on the next call will be parsed for signs that Boston Scientific either stabilizes EP or continues to lose ground.

That’s why risk management matters here. BSX offers defined levels: support in the low $60s, resistance near $65, and a crowded zone of Street targets above. For short‑term setups, traders also need to respect the basics of technical and catalyst‑driven trading. As Tim Bohen, lead trainer with StocksToTrade says, “A good trade setup checks all the boxes—volume, trend, catalyst. Don’t trade if you’re missing pieces of the puzzle.” As Tim Sykes loves to remind traders, “The stock market doesn’t owe you anything — that’s why you always cut losses quickly and let the best setups come to you.” For Boston Scientific, the next earnings print will show whether BSX is one of those best setups, or just another crowded rebound that runs out of steam.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!